Mingyue Li, Ph.D.
Affiliations: | 2006 | The Chinese University of Hong Kong, Hong Kong, Hong Kong |
Area:
Neurodevelopment and NeurodegenerationGoogle:
"Mingyue Li"Mean distance: 15.04 (cluster 6) | S | N | B | C | P |
Parents
Sign in to add mentor| Gong Chen | grad student | 2006 | Chinese University of Hong Kong | |
| (The anti-tumor mechanism of PPARgamma activator troglitazone in human lung cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang S, Li MY, Liu Y, et al. (2020) The Role of microRNA in Cisplatin Resistance or Sensitivity. Expert Opinion On Therapeutic Targets |
| Ren J, Liu Y, Wang S, et al. (2020) The FKH domain in FOXP3 mRNA frequently contains mutations in hepatocellular carcinoma that influence the subcellular localization and functions of FOXP3. The Journal of Biological Chemistry |
| Liu LZ, Wang M, Xin Q, et al. (2020) The permissive role of TCTP in PM/NNK-induced epithelial-mesenchymal transition in lung cells. Journal of Translational Medicine. 18: 66 |
| Jia H, Qi H, Peng J, et al. (2019) FOXP3Δ3, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii5-ii6 |
| Wang N, Li MY, Liu Y, et al. (2019) ZBP-89 negatively regulates self-renewal of liver cancer stem cells via suppression of Notch1 signaling pathway. Cancer Letters |
| Qi H, Wang S, Wu J, et al. (2019) EGFR-AS1/HIF2A regulates the expression of FOXP3 to impact the cancer stemness of smoking-related non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 11: 1758835919855228 |
| Jia H, Qi H, Gong Z, et al. (2019) The expression of FOXP3 and its role in human cancers. Biochimica Et Biophysica Acta. Reviews On Cancer |
| Wang N, Wang S, Li MY, et al. (2018) Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Therapeutic Advances in Medical Oncology. 10: 1758835918816287 |
| Niu LL, Cheng CL, Li MY, et al. (2018) ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. Cell Death & Disease. 9: 852 |
| Wang N, Wang S, Yang SL, et al. (2018) Targeting ZBP-89 for the treatment of hepatocellular carcinoma. Expert Opinion On Therapeutic Targets |